Anti-IgE Drug Scratches Itch of Chronic Hives (CME/CE)
BALTIMORE (MedPage Today) -- The anti-immunoglobulin E (IgE) monoclonal antibody omalizumab (Xolair) durably eased itch severity in chronic urticaria uncontrolled by antihistamines, a pivotal trial showed. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 13, 2013 Category: Allergy & Immunology Source Type: news
A potential breakthrough for peanut allergy treatment
Peanut allergies are among the most rapidly growing food allergies in the United States. Millions of children are currently living with the condition, with new cases being diagnosed daily. (A recent study shows the number of reported peanut allergies tripled in just over a decade.) And because allergic reactions to peanuts tend to be the most severe—80 to 95 percent of all food allergy deaths are peanut or tree nut related—the trend is a serious cause for concern.
But a small pilot study published by the Journal of Allergy and Clinical Immunology, may offer hope for the hundred of thousands of families living with the ...
Source: Thrive, Children's Hospital Boston - November 4, 2013 Category: Pediatrics Authors: Tripp Underwood Tags: All posts Food allergies Kids' safety Milk allergies Parenting clinical trial food allergy Dale Umetsu Lynda Schneider peanut allergies Rima Rachid Source Type: news
FDA files Genentech's supplemental biologics license application of Xolair (omalizumab) for chronic idiopathic urticaria (CIU)
CIU is a skin condition characterized by red, swollen, itchy hives on the skin. Currently, H1-antihistamines are the only approved therapy for patients suffering from CIU, also known as chronic spontaneous urticaria (CSU). FDA decision on sBLA expected during second quarter of 2014. Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair (omalizumab) in people with chronic idiopathic urticaria (CIU), a form of chronic hives who remained symptomatic despite treatment with H1-antihistamin...
Source: Roche Investor Update - October 11, 2013 Category: Pharmaceuticals Source Type: news
Omalizumab Reduces Itch of Severe Chronic UrticariaOmalizumab Reduces Itch of Severe Chronic Urticaria
Swiss drugmaker Novartis said on Saturday its drug omalizumab (Xolair) proved significantly more effective than placebo for patients with a severe form of hives in a late-stage study. Reuters Health Information (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - October 7, 2013 Category: Emergency Medicine Tags: Dermatology News Source Type: news
Novartis says drug reduces itch of severe chronic hives
ZURICH (Reuters) - Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Omalizumab and recent NICE guidance
This review will provide an overview of the changing NICE guidance, the evidence on which those guidelines are based and a practical approach to the use of omalizumab (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 2, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Xolair May Work for Nonallergic Asthma, Too (CME/CE)
(MedPage Today) -- The monoclonal antibody omalizumab (Xolair), used for allergic asthma, may be helpful for nonallergic cases as well, a proof-of-concept study showed. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 11, 2013 Category: Pediatrics Source Type: news
Omalizumab Significantly Improves Itch In Patients With Severe Form Of Chronic Skin Disease CSU, New Study
Novartis has announced late-breaking results showing omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria (CSU)1, a chronic and debilitating form of hives with limited approved treatment options2-4. The data was presented for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization (EAACI-WAO) World Allergy and Asthma Congress 2013 in Milan, Italy. Omalizumab is not currently approved or indicated for CSU... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 2, 2013 Category: Consumer Health News Tags: Dermatology Source Type: news
Omalizumab in patients with severe form of chronic skin disease
Novartis has announced late-breaking results showing omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria (CSU), a chronic and debilitating form of hives with limited approved treatment options. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 26, 2013 Category: Drugs & Pharmacology Source Type: news
Novartis skin drug helps patients with chronic hives
ZURICH (Reuters) - Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - June 26, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Asthma experts call for introduction of drug which has ‘Lazarus-like’ effect on patients
Xolair has just been approved in the UK but access to it in Ireland is limited (Source: The Irish Times - Health)
Source: The Irish Times - Health - April 30, 2013 Category: Consumer Health News Source Type: news
Omalizumab May Help Kids With Uncontrolled Allergic AsthmaOmalizumab May Help Kids With Uncontrolled Allergic Asthma
Children with severe refractory allergic asthma may benefit from adding omalizumab (Xolair, Roche/Genentech, Novartis), French clinicians say. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Dermatologists Offer Hope To Patients With Chronic Urticaria
An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2013 Category: Consumer Health News Tags: Dermatology Source Type: news
A step forward in the treatment of chronic urticaria
(IMIM (Hospital del Mar Medical Research Institute)) An international study involving dermatologists from the Hospital del Mar and IMIM has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2013 Category: Global & Universal Source Type: news
NICE Turnaround On Novartis' Xolair To Be Discussed At Asthma & Copd Conference, 15-16 April 2013, London
The UK's National Institute for Health and Clinical Excellence (NICE) has recently recommended Xolair, Novartis as an option for treating severe, persistent allergic asthma in adults, adolescents and children. The decision comes as a result of a move by Novartis to offer a patient access scheme to discount Xolair's list price. An estimated 65 million people currently suffer from COPD globally with 300 million asthma sufferers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 18, 2013 Category: Consumer Health News Tags: Conferences Source Type: news
